Figure 3
From: CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
Gene expression changes in malignant B cells and plasma cells of MYC- and/or IL-6-transgenic mice. Shown are mean values and standard deviations of qPCR results obtained in triplicate. The results of Kruskal-Wallis comparisons of median gene expression values are indicated to the upper right. (A) Cdkn1a (cyclin-dependent kinase inhibitor 1A) and Trp53 (transformation related protein 53) encode the tumor suppressors p21 and p53, respectively. Fancd2, Fanconi anemia, complementation group D2; Xrcc6, complementation X-ray repair complementing defective repair in Chinese hamster cells 6. (B) Aurka, aurora kinase A; Prdm1, PR domain containing 1, with ZNF domain (aka Blimp-1); Irf1, interferon regulatory factor 1; Egr1, early growth response 1; Bcl2, B cell leukemia / lymphoma 2. Wild-type status of Cdkn1a/p21 sequence was confirmed by DNA sequencing in eight tumors from C.IL6/iMyc∆Eμ mice (data not shown).